VB10.NEO

BIOLOGICAL2 trials

Sponsors

Nykode Therapeutics ASA

Conditions

Locally Advanced or Metastatic Solid TumoursSolid Tumors, Adult

Phase 1

A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer

CompletedNCT03548467

Nykode Therapeutics ASALocally Advanced or Metastatic Solid Tumours

Start: 2018-04-04End: 2023-01-30Updated: 2023-04-21

Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

CompletedNCT05018273

Nykode Therapeutics ASASolid Tumors, Adult

Start: 2021-12-21End: 2024-10-09Updated: 2024-12-03

Related Papers

Induction of neoantigen-specific immune responses by VB10.NEO in combination with atezolizumab in heavily pretreated patients with advanced solid tumors: Final analysis of the phase 1b VB N-02 trial.

Journal of Clinical Oncology2025-05-281 citations

Abstract CT217: An open-label, Phase I/IIa study of VB10.NEO (DIRECT-01) in combination with checkpoint blockade in patients with locally advanced or metastatic solid tumors including melanoma, NSCLC, renal cell carcinoma, urothelial cancer or SSCHN

Cancer Research2019-07-015 citations

Abstract CT217: An open-label, Phase I/IIa study of VB10.NEO (DIRECT-01) in combination with checkpoint blockade in patients with locally advanced or metastatic solid tumors including melanoma, NSCLC, renal cell carcinoma, urothelial cancer or SSCHN

Clinical Trials2019-07-01